GRND · Investment summary · as of 12 August 2026
Priced below what the business already delivers
Business type: Compounder
Size is the strategy's, set against its own position and exposure limits.
At $16.23, GRND requires a 10% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 32%.
Both axes clear by >20pp; the live disagreement with the market is growth durability (how long 30%+ compounds), not margin.
The conditions that would settle the disagreement are dated to December 2026.
The value rests on an exit multiple of 15.0x, a terminal operating margin of 30% and a 8.1% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Advertising revenue is $24,871k in Q2'26 (18.0% of revenue, +44.0% YoY -- decelerating from +68.0% in Q1) and the audience attribute sold IS the protected characteristic at issue.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Both axes clear by >20pp; the live disagreement with the market is growth durability (how long 30%+ compounds), not margin. |
| What do we forecast? | Revenue growth of 32% demonstrated; a terminal operating margin of 30%; an exit multiple of 15.0x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +22.7 percentage points. |
| What is it worth? | Twelve-month target $18.15, +12% from the struck price. Scenario-weighted expected return net of costs +2.7%. |
| Why now? | The first dated test of the thesis falls on 31 December 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 31 December 2026 | Average Paying Users | Average Paying Users at or above 1,480 thousand in the quarter ended 31 December 2026 (i.e. under ~+10% YoY against… | Average Paying Users below 1,480 thousand in the quarter ended 31 December 2026 (i.e. under ~+10% YoY against Q4'25). |
| any two consecutive quarters through Q4 2027 | Average App-Based Revenue per Average Paying User | ARPPU at or above $26.51 (the Q2'26 level) in two consecutive quarters at any point through FY2027. | ARPPU below $26.51 (the Q2'26 level) in two consecutive quarters at any point through FY2027. |
| Q3 2026 (reported ~early Nov 2026) | Advertising revenue YoY growth | Neither leg of the condition opposite is met at this date | Advertising revenue grows less than +25% YoY in the quarter ended 30 September 2026. |
| any quarter through Q4 2027 | Total debt; net debt / TTM adjusted EBITDA | Total debt at or below $450,000k, or net debt / TTM adjusted EBITDA above 2.5x, on any quarterly balance sheet through… | Total debt above $450,000k, or net debt / TTM adjusted EBITDA above 2.5x, on any quarterly balance sheet through FY2027. |
Advertising revenue is $24,871k in Q2'26 (18.0% of revenue, +44.0% YoY -- decelerating from +68.0% in Q1) and the audience attribute sold IS the protected characteristic at issue. If a larger EEA regulator applies the Norwegian reasoning at scale, the targeted portion of that line stops rather than de-rates. SECOND NAMED CAUSE, co-equal and mechanically distinct: app-store removal or restriction in specific jurisdictions -- 82.0% of revenue is app-based and 'primarily processed through the in-app payment systems provided by Apple and Google' (10-Q), two counterparties with unilateral discretion over both distribution and collection, for a product criminalised in a material number of operating jurisdictions.
Estimated probability 12%, against the 20% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $18.15 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Advertising revenue is $24,871k in Q2'26 (18.0% of revenue, +44.0% YoY -- decelerating from +68.0% in Q1) and the audience attribute sold IS the protected characteristic at issue. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +22.7 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: advertising revenue is $24,871k in Q2'26 (18.0% of revenue, +44.0% YoY -- decelerating from +68.0% in Q1) and the audience attribute sold IS the protected characteristic at issue. The next evidence that should change the portfolio decision is the test dated 31 December 2026, or a daily close below $13.91, which forces an immediate review.